BFC
NGM

Bedel Financial Consulting’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Bedel Financial Consulting’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$2K – 971
2022
Q1 		$2K Hold
100
– – ﹤0.01% 903
2021
Q4 		$2K Hold
100
– – ﹤0.01% 915
2021
Q3 		$2K Hold
100
– – ﹤0.01% 910
2021
Q2 		$2K Hold
100
– – ﹤0.01% 903
2021
Q1 		$3K Buy
+100
New +$2.8K ﹤0.01% 825

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Bedel Financial Consulting's NGM Position: Q2 2022 in Review

Bedel Financial Consulting sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 100 shares — an estimated $2K sold.

Bedel Financial Consulting first reported a position in NGM in Q1 2021 and held it in 5 quarters. The position peaked at $3K in Q1 2021. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

  • Bedel Financial Consulting reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 100 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • Bedel Financial Consulting first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Bedel Financial Consulting's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.